Physician profile
Rahmath U Begum
NPI 1508170853
$4,181.57
in general payments reported to CMS, 2019-2025
24 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.70 · 2020: $442 · 2021: $895 · 2022: $588 · 2023: $623 · 2024: $920 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,060.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $602.53 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $497.00 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $419.86 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $342.98 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $226.85 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.57 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.27 | 2020-2022 | |
| Mylan Specialty L.P. | $89.68 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $87.63 | 2022-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $80.89 | 2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $63.94 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $54.35 | 2021-2023 | Gvoke Hypopen |
| Dexcom, INC. | $52.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.79 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $41.03 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.27 | 2025 | Trelegy Ellipta, Arexvy |
| Daiichi Sankyo INC. | $34.77 | 2021-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $18.75 | 2021 | |
| Exact Sciences Corporation | $18.21 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.47 | 2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $17.33 | 2020 | |
| Genentech USA, INC. | $12.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahmath Begum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.